Primary open-angle glaucoma (POAG) is a chronic, progressive, usually bilateral disease of the eye with an insidious onset.
It is most often characterized by optic nerve damage, defects in the retinal fiber layer and subsequent visual field loss in the absence of underlying ocular disease or congenital abnormalities.
It is generally asymptomatic until it has caused a significant loss of visual field.
Occasionally, patients with very high intraocular pressure may complain of nonspecific headache, discomfort, intermittent blurring of vision or even halos caused by corneal edema.
Canadian Ophthalmological Society Glaucoma Clinical Practice Guideline Expert Committee; Canadian Ophthalmological Society. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol. 2009;44(Suppl Suppl 1):S7-S93. doi: 10.3129/cjo44s1. Accessed 10 Feb 2012. PMID: 19492005
Broan AM, Garcger CP, Sirbat D, et al. Comparison of two fixed beta-blocker-pilocarpine combinations. The Carteolol-Pilocarpine Study Group. Eur J Ophthalmol. 1997;7(4):351-356. Accessed 10 Feb 2012. PMID: 9457458
Demailly P, Allaire C, Bron V, Trinquand C. Effectiveness and tolerance of beta blocker/pilocarpine combination eye drops in primary open-angle glaucoma and high intraocular pressure. J Glaucoma. 1995 Aug;4(4):235-241. Accessed 10 Feb 2012. PMID: 19920680
European Glaucoma Society. Terminology and guidelines in glaucoma. 3rd. Italy: European Glaucoma Society; 2008.
South East Asia Interest Group. Asia Pacific glaucoma guidelines. 2nd ed. Sydney, Australia: SEAGIG; 2008
Henderson P, Labbe T, Kass MA. Ocular hypertension. In: Yanoff M, Duker JS, Augsburger JJ, et al. Yanoff & Duker: Ophthalmology. 3rd ed. Maryland Heights, MO: Mosby, Inc; 2008
Japan Glaucoma Society. Guidelines for glaucoma. 2nd ed. Japan Glaucoma Society. http://ryokunaisho.jp/. Sep 2006. Accessed 31 Aug 2012.
National Collaborating Centre for Acute Care. Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension. National Institute for Health and Care Excellence. http://www.nice.org.uk/. Apr 2009. Accessed 03 Feb 2012.
American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Guidelines. Primary open-angle glaucoma. San Francisco, CA: American Academy of Ophthalmology. http://one.aao.org/summary-benchmark-detail/primary-openangle-glaucoma-suspect-summary-benchma. Oct 2013
American Optometric Association Original Consensus Panel on Care of the Patient with Open-Angle Glaucoma. Optometric clinical practice guideline care of the patient with open-angle glaucoma. American Optometric Association. http://www.aoa.org/documents/CPG-9.pdf. 2010. Accessed 03 Feb 2012
International Council of Ophthalmology. Primary open-angle glaucoma: initial evaluation. International Council of Ophthalmology. http://www.icoph.org/dynamic/attachments/resources/icopoaglaucomainev_2.pdf. 2010. Accessed 04 Feb 2012
International Council of Ophthalmology. Primary open-angle glaucoma: follow-up evaluation. International Council of Ophthalmology. http://www.icoph.org/dynamic/attachments/resources/icopoaglaucomafu_2.pdf. 2010. Accessed 04 Feb 2012
International Council of Ophthalmology. Primary open-angle glaucoma suspect: initial evaluation and follow-up. International Council of Ophthalmology. http://www.icoph.org/dynamic/attachments/resources/icopoagsuspect_2.pdf. 2010. Accessed 06 Feb 2012
Jacobs DS. Open-angle glaucoma: epidemiology, clinical presentation, and diagnosis. UpToDate. https://www.uptodate.com. 31 Jul 2019. Accessed 12 Oct 2015.
Jacobs DS. Open-angle glaucoma: treatment. UpToDate. https://www.uptodate.com. 23 Apr 2019. Accessed 12 Oct 2015.
European Glaucoma Society (EGS). Terminology and guidelines for glaucoma. 4th ed. EGS. http://www.eugs.org/eng/EGS_guidelines4.asp. Jun 2014.
Asian Pacific Glaucoma Society. Asia Pacific glaucoma guidelines. APGS. 3rd ed. Amsterdam: Kugler Publications; 2016.
Gross RL, McMillan BD. Current medical management of glaucoma. In: Yanoff M, Duker JS, eds. Ophthalmology. 5th ed. Philadelphia, Pennsylvania, USA: Saunders, Elsevier; 2019. 1120-1125. :1120-1125.
International Council of Ophthalmology (ICO). ICO guidelines for glaucoma eye care. ICO. http://www.icoph.org. 2015.
Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm. 2005 Apr;62(7):691-699. doi: 10.1093/ajhp/62.7.691. PMID: 15790795
Lusthaus J, Goldberg I. Current management of glaucoma. Med J Aust. 2019 Mar;210(4):180-187. doi: 10.5694/mja2.50020. PMID: 30767238
MacIver S, MacDonald D, Prokopich CL. Screening, diagnosis, and management of open angle glaucoma: an evidence-based guideline for Canadian optometrists. Can J Optometry. 2017;79(Suppl 1).
Ministry of Health Malaysia. Clinical practice guideline: management of glaucoma (2nd edition). http://www.acadmed.org.my. Jun 2017.
National Health and Medical Research Council. NHMRC guidelines for the screening, prognosis, diagnosis, management and prevention of glaucoma 2010. NHMRC. https://www.nhmrc.gov.au. 2010.
National Institute for Health and Care Excellence (NICE). Glaucoma: diagnosis and management. NICE. http://www.nice.org.uk. 01 Nov 2017.
Optometry Australia. Clinical practice guidelines for the diagnosis, treatment and management of glaucoma. https://www.optometry.org.au. Jul 2016.
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.